Oragenics, Inc. announced in September 2024 that it closed a public offering, raising approximately $4.45 million. This financing contributed to a total of over $6 million raised throughout the year.
These funds are designated to support the continued development of ONP-002, the company's lead candidate for concussion treatment. The capital infusion is crucial for advancing towards Phase II clinical trials.
The successful capital raise provides necessary resources for Oragenics to pursue its mission of addressing the unmet medical need for concussion treatments. It underscores the company's ability to secure funding for its pipeline.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.